首页> 外文期刊>Artificial Organs >Prismaflex HF20 for continuous renal replacement therapy in critically ill children.
【24h】

Prismaflex HF20 for continuous renal replacement therapy in critically ill children.

机译:Prismaflex HF20用于危重症儿童的连续肾脏替代治疗。

获取原文
获取原文并翻译 | 示例
           

摘要

Continuous renal replacement therapy (CRRT) in neonates and infants is complicated because of problems with venous cannulation, high or low surface of filters, and high volume of the circuit. We have recently published a longer unicentric European series of CRRT in 174 critically ill children (1). Of the patients, 48.3% weighed less than 10 kg, and 22% less than 5 kg (1). In these patients, we used M10 (0.04 m~2) or M60 (0.6 m~2) filters (Hospal,Lyon,France). However,M10 filters have a very lew surface area (and their capacity of depuration is low) and high resistance, and they produce frequent coagulation problems. In the last years, Prismaflex HF20 (Hospal) with a surface of 0.2 m~2 has been developed. A recent work has analyzed the use of HF20 in stable infants with chronic kidney insufficiency (2). However, there are no studies that have analyzed its efficiency in acute kidney injury (AKI) in a critical care setting. This is the aim of our study.
机译:由于静脉插管,滤器表面过高或过低以及回路容积大等问题,新生儿和婴儿的连续肾脏替代疗法(CRRT)十分复杂。我们最近在174名重症儿童中发表了更长的单中心欧洲CRRT系列文章(1)。在这些患者中,48.3%的体重不足10公斤,22%的体重不足5公斤(1)。在这些患者中,我们使用了M10(0.04 m〜2)或M60(0.6 m〜2)过滤器(Hospal,法国里昂)。但是,M10过滤器的表面积很小(净化能力很低)并且阻力很高,并且经常出现凝结问题。近年来,已开发出表面为0.2 m〜2的Prismaflex HF20(Hospal)。最近的一项工作分析了HF20在患有慢性肾功能不全的稳定婴儿中的使用(2)。但是,尚无研究分析其在重症监护环境中对急性肾损伤(AKI)的有效性。这是我们研究的目的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号